Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

627
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
627
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

1.0K
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

554
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
554
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.3K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.3K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

1.2K
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

60 years of ARDS and the evolution of extracorporeal lung support - from ECMO to ECCO<sub>2</sub>R.

Intensive care medicine·2026
Same author

ECMO for patients with obesity: evidence and practice.

Intensive care medicine·2026
Same author

How to optimize brain perfusion and prevent cerebral complications during extracorporeal life support.

Intensive care medicine·2026
Same author

Palliative and End-of-Life Care Utilization in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Population-Based Study.

JACC. Advances·2026
Same author

Long-term quality of life and functional outcomes in extracorporeal membrane oxygenation survivors.

JHLT open·2026
Same author

Visual Right Ventricular Assessment in ICU: A Multicenter International Study.

Critical care medicine·2026

Related Experiment Video

Updated: Mar 3, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
03:40

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

915

Extracorporeal Membrane Oxygenation for Acute Decompensated Heart Failure.

Laurence Dangers1, Nicholas Bréchot, Matthieu Schmidt

  • 11Service de Réanimation, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.2Sorbonne Universités, UPMC Université Paris 06, INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France.3Service de Chirurgie Thoracique et Cardiovasculaire, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

Critical Care Medicine
|May 5, 2017
PubMed
Summary

Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) offers a 42% 1-year survival for acute decompensated heart failure patients. Lower pre-implantation Sequential Organ Failure Assessment scores indicate better outcomes, emphasizing timely VA-ECMO initiation.

More Related Videos

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
06:41

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

13.1K
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 3, 2026

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
03:40

Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting

Published on: January 17, 2025

915
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
06:41

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse

Published on: October 24, 2018

13.1K
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.4K

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Cardiovascular Surgery

Background:

  • Long-term outcomes of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) for acute decompensated heart failure (ADHF) remain underreported.
  • ADHF, often complicated by cardiogenic shock in chronic cardiomyopathy, requires advanced support strategies.

Purpose of the Study:

  • To describe the long-term outcomes of patients treated with VA-ECMO for ADHF.
  • To identify factors associated with mortality in this patient population.

Main Methods:

  • Retrospective analysis of prospectively collected data from 105 patients with ADHF treated with VA-ECMO.
  • Data included pre-implantation Sequential Organ Failure Assessment (SOFA) scores, cardiac disease duration, and blood lactate levels.

Main Results:

  • The 1-year survival rate was 42%.
  • Independent predictors of 1-year mortality included higher pre-ECMO SOFA scores (>11), idiopathic cardiomyopathy, longer cardiac disease duration (>2 years), and elevated pre-ECMO blood lactate (>4 mmol/L).
  • Patients with pre-ECMO SOFA scores < 11 had significantly better survival rates.

Conclusions:

  • VA-ECMO is a viable option for ADHF, with a 42% 1-year survival in this cohort.
  • Optimal timing of VA-ECMO implantation, guided by pre-procedural assessment (e.g., SOFA score), is critical for improving patient outcomes.